相关实验视频
Updated: Sep 9, 2025

04:23
Application of Hemostatic Devices in Laparoscopic Hepatectomy
Published on: April 19, 2022
2.3K
避免电:在莫斯微图外科手术中治疗外科手术期间出血的止血剂
George M Jeha1,2, Hannah R Malinosky1, Jacob Beer3
1Louisiana State University Health Sciences Center, New Orleans, Louisiana.
概括
局部止血剂在莫斯手术期间有效减少出血,特别是在服用血液稀释剂的患者中. 这些药物有望改善外科手术期间的血静,需要进一步研究.
科学领域:
- 皮肤外科
- 手术血液静止
- 药理学
背景情况:
- 在莫斯微图手术中, 出血是常见的并发症.
- 增加抗凝剂和抗血小板剂的使用会增加出血风险.
- 在莫斯手术中需要有效的外科静血策略.
研究的目的:
- 系统地审查有关Mohs手术的局部/局部止血剂的文献.
- 评估辅助静血方法的有效性和安全性.
- 确定在莫斯手术期间和之后减少出血的药物.
主要方法:
- 系统的文献搜索 (PubMed,Scopus,Cochrane,EMBASE) 至 2024 年 3 月.
- 包括局部注射或局部注射的血静剂的原始研究.
- 分析了7项涉及458名患者的研究.
主要成果:
- 评估的药物包括松酸,布里莫尼丁凝,静血粉末和微孔多糖物质.
- 药物通常被患者很好地容忍.
- 观察到手术内和手术后出血的减少.
结论:
- 局部注射的止血剂是莫斯手术中血液控制的有希望的辅助剂.
- 这些药物可能对高危出血患者特别有益.
- 建议进行进一步的大规模受控研究.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
888
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
888
Introduction to Hemostasis
8.9K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
8.9K
Extrinsic and Intrinsic Pathways of Hemostasis
9.1K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
9.1K
Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Disorders of Hemostasis
1.2K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.2K

